IMR Press / RCM / Special Issues / diabetic_cardiomyopathy

Recent Advances in Diabetic Cardiomyopathy

Section: Heart Diseases
Submission deadline: 30 June 2024
Special Issue Editors
  • Djamel Lebeche, PhD, FAHA, FACC
    Department of Physiology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, USA
    Interests: pathobiology of diabetes-induced heart failure; functional genemics of cardiometabolism; diabetes drug discovery
  • Abdul Majid, PhD
    Department of Physiology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, USA
    Interests: pre-diabetes; bioactive compounds; cardiomyopathy; bone health and peptides
Special Issue Information

Dear Colleagues,

Clinicians have long recognized the link between diabetes mellitus and heart disease. A significant number of diabetic patients exhibit diabetic cardiomyopathy; that is, left ventricular dysfunction independent of coronary artery disease or hypertension. Diabetic cardiomyopathy is a complex disease with multifactorial pathogenesis that is essentially driven by dynamic structural, molecular, metabolic, and genetic/epigentic alterations. Moreover, complex crosstalk between diverse cell populations and cellular organelles within the myocardium as well as the interaction of the various defects have further complicated the search for the precise molecular mechanims underpinning the disease. Undeniably, over the past decade, our understanding of the pathological features of diabetic cardiomyopathy has increased, yet a unifying hypothesis of the various pathophysiological pathways and the route causes of the disease remains a pertinant question. Several current therapies can effectively treat hyperglycemia and hyperlipidemia. However, many have adverse cardiovascular effects, and none of them directly targets the cardiac manifestations of diabetes.

This research topic will explore the temporal onset of diabetic cardiomyopathy and focus on new insights and developments in cardiac diabetes research, novel experimental approaches, current challenges and the latest discoveries in therapeutic modalities, as well as recent advances and future perspectives in the field of diabetes-induced heart failure. The goal of this special issue is to inform and provide a thorough overview of diabetic cardiomyopathy research over the past decade. It should also shed light on the progress made so far, and highlight future challenges regarding the clinical impact of emerging treatments that improve cardiovascular outcomes.

A variety of article types are welcome, including Original Research, Communication, Commentary, (Mini)-Review, Systematic Review, and Editorial. Potential areas of interest in the field of diabetic cardiomyopathy include, but are not limited to:

  • Pathophysiology, mechanisms, and treatments.
  • Diagnostic approaches for diabetic cardiomyopathy.
  • Molecular mechanisms and Signaling Pathways of diabetic cardiomyopathy.
  • RNA-based mechanisms (non-coding RNAs - lncRNA, miRNA, CircRNAs; epitranscriptomics, etc.)
  • Genetics, Epigenetics/Epigenomics regulation.
  • Role of Pyroptosis and its regulation.
  • Endothelial dysfunction.
  • Impairment of mitophagy and mitochondrial dysfunction.
  • Inflammation and immune response.
  • Ca2+ dyshomeostasis.
  • Structural remodeling, cytoskeletal remodeling, ECM remodeling, metabolic remodeling.
  • Hyperglycemic memory in diabetic cardiomyopathy.
  • Role of hyperglycemia and sugar alternatives/nonnutritive sweeteners.
  • The gut microbiota and diabetic cardiomyopathy.
  • ER quality control and Mitochondrial quality control in diabetic cardiomyopathy.
  • Current therapeutic approaches, Challenges facing current therapies.
  • New therapies based on gene delivery, cell replacement, SGLT-2 inhibitors, etc.
  • Alternative therapies: Novel bioactive compounds and peptides.
  • Preclinical models of diabetic cardiomyopathy; Modelling Using Induced Pluripotent Stem Cells.
  • Covid-19 and diabetic cardiomyopathy.

Prof. Djamel Lebeche Dr. Abdul Majid
Guest Editors

diabetes mellitus
diabetic cardiomyopathy
heart failure
cardiac fibrosis
cardiomyocyte hypertrophy
diastolic dysfunction
hyperglycemia, hyperlipidemia
molecular imaging
non-coding RNAs
mitochondrial dysfunction
immune response
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (2 Papers)
Back to top